C
Clinuvel Pharmaceuticals Ltd D
D
CUVL
5.87000
USD
-0.09
(-1.51%)
Market Closed
Volume
0
EPS
0
Div Yield
0.61
P/E
12
Market Cap
296,011,761
Title: Clinuvel Pharmaceuticals Ltd
Sector: Healthcare
Industry: Biotechnology
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
